Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (248)

« Back to Publications

Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data.

Coleman RL. et al, (2026), Diabetes Obes Metab, 28, 1068 - 1075

Challenges and Recommendations for Integrating Circadian Medicine in Critical Care: A Roadmap.

Hiemstra FW. et al, (2025), Chest

Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis.

Bidel Z. et al, (2025), Eur Heart J

Has the WHO Model Essential Medicines List lost its way?

Beran D. et al, (2025), Lancet Diabetes Endocrinol, 13, 999 - 1000

ssessing the representativeness of trials of Sodium-glucose Cotransporter-2 inhibitors in type 2 diabetes: a comparison of individual-level trial data and people newly prescribed treatment in a Welsh routine care database.

Hanlon P. et al, (2025), BMC Med, 23

International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL.

Clarke PM. et al, (2025), Diabetes Care, 48, 1925 - 1931

cohort description and comparison of four European national diabetes registries for the REDDIE project.

Thomas JJC. et al, (2025), Diabet Med, 42

ssessing the efficacy, safety and utility of hybrid closed-loop glucose control compared with standard insulin therapy combined with continuous glucose monitoring in young people (≥16 years) and adults with cystic fibrosis-related diabetes (CL4P-CF study): protocol for an open-label, multicentre, randomised, two-arm and single-period parallel trial

Kadiyala N. et al, (2025), BMJ Open, 15

Missing Pieces of the Puzzle to Address Market Failures for Antibiotics: Delinked Payment Systems and Insurance Value.

Hawkins N. et al, (2025), Pharmacoecon Open, 9, 707 - 712

Comparative effectiveness of alternative second-line oral glucose-lowering therapies for type 2 diabetes: a precision medicine approach applied to routine data.

O'Neill S. et al, (2025), Diabetologia, 68, 1908 - 1923

Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.

Coleman RL. et al, (2025), Cardiovasc Diabetol, 24

Long-term outcomes following alternative second-line oral glucose-lowering treatments: Results from the real-world progression in type 2 diabetes mellitus United Kingdom (RAPIDS-UK) model.

Carroll OU. et al, (2025), Diabetes Obes Metab, 27, 4181 - 4191

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Gillessen S. et al, (2025), Lancet Oncol, 26, 1018 - 1030

Glucocorticoid-induced hyperglycaemia in hospitalised adults: A matched cohort study (2013-2023).

Golubic R. et al, (2025), Diabetes Obes Metab, 27, 3635 - 3644

systematic review of in vivo brain insulin resistance biomarkers in humans

Reid G. et al, (2025), Biomarkers in Neuropsychiatry, 12

Load More

1
2
3
4
5
6
7
...
»